Followers | 368 |
Posts | 5333 |
Boards Moderated | 1 |
Alias Born | 05/09/2013 |
Wednesday, April 18, 2018 4:25:03 PM
It's right there in the recent earnings report (below). Anyone can easily see it with 1 minute's worth of due diligence. Whoever said that ALT is low on cash to find operations is ignorant or has very-very high standards for funding needs.
As one of my criteria, I always make sure these biotechs have approx 1+ Year's worth of cash before I even consider it, watch it, or trade it for the short term. I also check standard loan/debt levels (excluding the share offerings/warrants), and ALT has a low loan debt level that's easily manageable, so very low risk of BK, too.
With a penny stock priced biotech, on average you're not going to get much better than 1-2 years of cash to fund operations. These biotechs typically price offerings on average annually. $ALT just did a public offering to raise cash a little while ago. &ALT is good financially in the short term. I would not be worried about more cash raising news until at least October - 4th Qtr 2018 or early Jan-Feb 2019.
If anyone cares about the longer term, then that's different, and as for me I don't associate longer term with these stocks because they're only good for short term trading. Longer Term thinking has no place wiht these stocks as they're trend long term typically is 99% of the time downward, but great for short term swing trading from oversold lows.
March 28, 2018
"Raised approximately $30 million in financing, including through a Series B preferred offering, cash acquired in connection with the reverse merger with PharmAthene and a pre-merger private placement with existing investors, providing cash into the first quarter of 2019"
https://finance.yahoo.com/news/altimmune-announces-financial-results-ended-204454692.html
***Go to my 'Profile' for more information on following me***
Recent ALT News
- CORRECTION – Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/10/2024 05:09:49 PM
- Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/10/2024 11:45:00 AM
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 10:05:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/15/2024 08:14:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/15/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/15/2024 08:03:03 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:07:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:04:52 AM
- Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update • GlobeNewswire Inc. • 08/08/2024 11:00:00 AM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:45:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:43:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 09:40:41 PM
- Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology • GlobeNewswire Inc. • 07/25/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 07/03/2024 09:45:00 AM
- Altimmune to Participate at Leerink Partners Therapeutics Forum • GlobeNewswire Inc. • 07/02/2024 11:30:00 AM
- Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm • PR Newswire (US) • 06/28/2024 09:45:00 AM
- Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt • GlobeNewswire Inc. • 06/26/2024 11:30:00 AM
- Shareholders that lost money on Altimmune, Inc.(ALT) should contact The Gross Law Firm about pending Class Action - ALT • PR Newswire (US) • 06/25/2024 09:45:00 AM
- Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions • GlobeNewswire Inc. • 06/23/2024 05:45:00 PM
- Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions • GlobeNewswire Inc. • 06/22/2024 08:45:00 PM
- Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM